5 results match your criteria: "University of Pittsburgh Alzheimer's Disease Research Center (ADRC)[Affiliation]"
Association of education attainment, smoking status, and alcohol use disorder with dementia risk in older adults: a longitudinal observational study.
Alzheimers Res Ther
September 2024
Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, FL, 32606, USA.
Article Synopsis
- - The study examined the effects of education, smoking, and alcohol use disorder (AUD) on dementia risk in older adults, aiming to understand how these factors might influence dementia differently among various subgroups.
- - Using data from the National Alzheimer's Coordinating Center (2005-2021), researchers found that a college education was linked to a decreased risk of dementia, particularly in people without hypertension, while smoking and AUD had varying effects based on specific health conditions.
- - The findings highlight the need for a personalized approach in addressing dementia risk, as different factors significantly impact certain groups, suggesting that interventions should be tailored to individual health profiles.
Heterogeneous treatment effects of sodium-glucose cotransporter 2 inhibitors on risk of dementia in people with type 2 diabetes: A population-based cohort study.
Alzheimers Dement
August 2024
Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA.
Article Synopsis
- SGLT2 inhibitors may help lower the risk of all-cause dementia in individuals with type 2 diabetes (T2D), with studies showing a significantly lower incidence compared to those taking sulfonylureas.
- In a study involving over 35,000 T2D patients, 1.8% on SGLT2 inhibitors developed dementia versus 4.7% on sulfonylureas, indicating a risk difference of -2.5% across a 3.2-year follow-up.
- Subgroup analysis revealed that Hispanic ethnicity and chronic kidney disease influenced the risk reduction, suggesting that not all patients with T2D benefit equally from SGLT2 inhibitors
Heterogeneous treatment effects of metformin on risk of dementia in patients with type 2 diabetes: A longitudinal observational study.
Alzheimers Dement
February 2024
Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida, USA.
Introduction: Little is known about the heterogeneous treatment effects of metformin on dementia risk in people with type 2 diabetes (T2D).
Methods: Participants (≥ 50 years) with T2D and normal cognition at baseline were identified from the National Alzheimer's Coordinating Center database (2005-2021). We applied a doubly robust learning approach to estimate risk differences (RD) with a 95% confidence interval (CI) for dementia risk between metformin use and no use in the overall population and subgroups identified through a decision tree model.
Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies.
J Am Geriatr Soc
July 2023
Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA.
Background: Preclinical studies have suggested potential beneficial effects of newer glucose-lowering drugs (GLDs) including dipeptidyl peptidase (DPP)-4 inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and sodium glucose co-transporter-2 (SGLT2) inhibitors, in protecting humans against cognitive decline and dementia. However, population studies aiming to demonstrate such cognitive benefits from newer GLDs have produced mixed findings. This meta-analysis aimed to evaluate the association between newer GLDs and risk of dementia in adults with type 2 diabetes (T2D).
View Article and Find Full Text PDFQuantitative amyloid imaging using image-derived arterial input function.
PLoS One
January 2016
Department of Radiology, Washington University School of Medicine, Saint Louis, Missouri, United States of America; Knight Alzheimer's Disease Research Center (ADRC), Washington University School of Medicine, Saint Louis, Missouri, United States of America; Department of Neurosurgery, Washington University School of Medicine, Saint Louis, Missouri, United States of America.
Amyloid PET imaging is an indispensable tool widely used in the investigation, diagnosis and monitoring of Alzheimer's disease (AD). Currently, a reference region based approach is used as the mainstream quantification technique for amyloid imaging. This approach assumes the reference region is amyloid free and has the same tracer influx and washout kinetics as the regions of interest.
View Article and Find Full Text PDF